Mining predictive biomarker for neoadjuvant chemotherapy in gastric cancer by proteomics.
In this study, we applied the SELDI-TOF-MS technique for the identification of gastric cancer-specific protein markers and sample SELDI protein profiling to distinguish gastric cancer patients of the efficacy of neoadjuvant chemotherapy from a no efficacy population. Gastric tissue samples from 8 paired patients with gastric cancer, from whom clinical and histopathological data concerning patients and carcinomas were available, were analyzed. We scanned 8 paired samples (chemotherapy sensitive and insensitive) by SELDI-TOF-MS. The data generated 409 high sensitive and reproducibly peaks. From the distribution of the peaks, most of the detectable peaks are in the range from 3000-7000m/z. One potential protein at 7044m/z is Guanine nucleotide-binding protein (GBG7_Human 060262). In summary, we present novel differential expressed protein profile for neoadjuvant chemotherapy. This data set will help us to understand the mechanism for the chemotherapy resistance. Our data suggested the presence of GBG7 indicate patient will receive better prognosis of neoadjuvant chemotherapy.